Lilly to acquire Ventyx Biosciences in a $1.2bn deal.

Lilly, a medicine company, agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company, in a $1.2bn deal. "Our portfolio of class-leading NLRP3 inhibitors modulate residual and chronic inflammation that is now recognized as a major risk factor in a host of neuroinflammatory, cardiometabolic and cardiovascular diseases. We believe that Lilly is an ideal strategic partner, with unparalleled resources, a passion for innovative oral drugs and a commitment to advance novel therapies that fill a vast unmet need for patients suffering from these debilitating diseases and disorders," Raju Mohan, Ventyx Biosciences chief executive officer.